WO2024071138A1 - Composition améliorant la fonction mitochondriale - Google Patents

Composition améliorant la fonction mitochondriale Download PDF

Info

Publication number
WO2024071138A1
WO2024071138A1 PCT/JP2023/035000 JP2023035000W WO2024071138A1 WO 2024071138 A1 WO2024071138 A1 WO 2024071138A1 JP 2023035000 W JP2023035000 W JP 2023035000W WO 2024071138 A1 WO2024071138 A1 WO 2024071138A1
Authority
WO
WIPO (PCT)
Prior art keywords
palmitic acid
improving
gene
mitochondrial function
present
Prior art date
Application number
PCT/JP2023/035000
Other languages
English (en)
Japanese (ja)
Inventor
結妃 船津
悠一 津田
Original Assignee
株式会社明治
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社明治 filed Critical 株式会社明治
Publication of WO2024071138A1 publication Critical patent/WO2024071138A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a composition for improving mitochondrial function.
  • the present invention also relates to a composition for enhancing expression of mitochondrial biogenesis-related genes.
  • Mitochondria are intracellular organelles that not only produce ATP, which is essential for intracellular energy metabolism, through aerobic respiration, but also play a wide range of metabolic roles, such as regulating oxidative stress, regulating intracellular Ca2+ concentration, controlling cell death, synthesizing phospholipids, synthesizing heme, and synthesizing steroids.
  • Fetal babies are in a relatively hypoxic state and generate energy through anaerobic glycolysis, but immediately after birth, babies are exposed to oxygen in the air and switch to aerobic respiration through mitochondria. Aerobic respiration through mitochondria is more efficient at producing energy than anaerobic respiration through glycolysis. In glycolysis, two molecules of ATP are produced per glucose molecule, whereas in aerobic respiration through mitochondria, 36 molecules of ATP are produced per glucose molecule. Therefore, it is thought that it is important for newborns and infants to quickly adapt to aerobic mitochondrial respiration in order to provide the energy required for rapid growth.
  • mitochondrial dysfunction is more likely to occur with age. This leads to a decrease in ATP production by mitochondria and an increase in the production of reactive oxygen species (ROS). Furthermore, these mitochondrial dysfunctions cause intracellular metabolic disorders and the accumulation of mitochondrial DNA mutations, leading to a vicious cycle, and mitochondrial dysfunction is thought to be a factor in promoting aging. Mitochondrial dysfunction has also been reported to be associated with various diseases such as cancer, neurodegenerative diseases, arteriosclerosis, and diabetes (Non-Patent Documents 1, 2, and 3).
  • the present invention aims to provide a novel composition for improving mitochondrial function.
  • the present invention also aims to provide a novel composition for enhancing the expression of mitochondrial biogenesis-related genes.
  • the present inventors have now found that the addition of ⁇ -palmitic acid to cultured human cells significantly increases ATP production compared to when ⁇ -palmitic acid is not added.
  • the present inventors have also found that the addition of ⁇ -palmitic acid to cultured human cells significantly increases Sirt3 gene expression levels, Nfe2l2 gene expression levels, and Tfam gene expression levels compared to when ⁇ -palmitic acid is not added or when ⁇ -oleic acid is added, and that there is a tendency for Nrf1 gene expression levels and Pgc-1 ⁇ gene expression levels to increase compared to when ⁇ -palmitic acid is not added.
  • the present inventors further found that the addition of ⁇ -palmitic acid to cultured human cells significantly increases the expression level of the Sirt3 gene compared to the addition of ⁇ -myristic acid or ⁇ -stearic acid, that the expression levels of the Nfe2l2 gene and the Tfam gene significantly increase compared to the addition of ⁇ -myristic acid, palmitic acid, or ⁇ -stearic acid, and that the expression level of the Nrf1 gene significantly increases compared to the addition of ⁇ -myristic acid.
  • the present invention is based on these findings.
  • a composition for improving mitochondrial function or an agent for improving mitochondrial function comprising an oil or fat containing ⁇ -palmitic acid as an active ingredient.
  • a composition for enhancing expression of a mitochondrial biogenesis-related gene or an agent for improving mitochondrial function comprising an oil or fat containing ⁇ -palmitic acid as an active ingredient.
  • the composition or agent described in [2] above, wherein the gene is one or more genes selected from the group consisting of Sirt3 gene, Nfe2l2 gene, and Tfam gene.
  • composition or agent according to any one of [1] to [4] above for use in promoting ATP production.
  • composition or agent according to any one of [1] to [5] above which is a food composition.
  • a method for improving mitochondrial function or enhancing expression of a mitochondrial biogenesis-related gene comprising having a subject in need thereof ingest an oil or fat containing an effective amount of ⁇ -palmitic acid or a composition containing the same.
  • a method for maintaining, improving, treating or preventing a disease or condition that can be maintained, improved, treated or prevented by improving mitochondrial function comprising having a subject in need thereof ingest an effective amount of an oil or fat containing ⁇ -palmitic acid or a composition containing the same.
  • Use of an oil or fat containing ⁇ -palmitic acid as an agent for improving mitochondrial function or an agent for enhancing mitochondrial biogenesis-related gene expression for the manufacture of an agent for improving mitochondrial function or an agent for enhancing mitochondrial biogenesis-related gene expression, or in a method for improving mitochondrial function or a method for enhancing mitochondrial biogenesis-related gene expression.
  • an oil or fat containing ⁇ -palmitic acid for the manufacture of an agent for maintaining, improving, treating, or preventing a disease or condition that can be maintained, improved, treated, or prevented by improving mitochondrial function, as an agent for maintaining, improving, treating, or preventing a disease or condition that can be maintained, improved, treated, or prevented by improving mitochondrial function, or in a method for maintaining, improving, treating, or preventing a disease or condition that can be maintained, improved, treated, or prevented by improving mitochondrial function.
  • compositions [1] to [6] above may be referred to as the “compositions of the present invention.”
  • agents [1] to [6] above may be referred to as the “agents of the present invention.”
  • the active ingredient of the composition and agent of the present invention is fat or oil that has been used as a food ingredient for many years. Therefore, the composition and agent of the present invention not only has the effect of improving mitochondrial function, but also has the advantage of being highly safe, with no risk of side effects even when taken continuously over a long period of time.
  • composition and agent of the present invention contain an oil containing ⁇ -palmitic acid as an active ingredient.
  • ⁇ -palmitic acid refers to a substance in which palmitic acid is bound to the ⁇ -position of a glyceride, and refers to all compounds that are identical in chemical formula.
  • ⁇ -palmitic acid is acylglycerol with palmitic acid bound to at least the ⁇ -position, and includes acylglycerol (monoacylglycerol) with palmitic acid bound to the ⁇ -position and an optional fatty acid bound to either of the two ⁇ -positions, and acylglycerol (triacylglycerol) with palmitic acid bound to the ⁇ -position and an optional fatty acid bound to each of the two ⁇ -positions.
  • ⁇ -palmitic acid may be a pure product or a mixture with other substances. For example, a raw material in which ⁇ -palmitic acid has been measured by a known measurement method and its presence has been confirmed may be used as is.
  • a typical example of a raw material (mixture) rich in ⁇ -palmitic acid is lard, which can also be used in the composition and agent of the present invention.
  • lard has a unique "animal odor," and in order to eliminate this odor, it is known that vegetable oils rich in palmitic acid are chemically or enzymatically modified to obtain raw materials rich in ⁇ -palmitic acid (JP-T-8-509620A, JP-T-8-509621A, JP-A-6-70786A).
  • a commercially available product of ⁇ -palmitic acid e.g., Betapol (Bunge, Roders, Krokran)
  • Betapol Bunge, Roders, Krokran
  • the lower limit of the ratio (mass ratio) of palmitic acid bound to the ⁇ -position (sn-2 position) of the glyceride relative to the total amount of fatty acids bound to the ⁇ -position can be set to 10%, preferably 50%, and more preferably 74%, from the viewpoint of better exerting the effects of the present invention.
  • the upper limit of the above ratio can be set to a range not exceeding 90%, preferably 85%, and more preferably 78%, from the viewpoint of stable production.
  • the lower limit of the ratio of palmitic acid at the ⁇ -position of glycerides to the total palmitic acid can be 50%, preferably 54%, more preferably 65%, even more preferably 67%, and particularly preferably 68%, from the viewpoint of better exerting the effects of the present invention.
  • the upper limit of the above ratio can be in a range not exceeding 98%, preferably 75%, more preferably 74%, even more preferably 73%, and particularly preferably 72%, from the viewpoint of stable production.
  • compositions and agents of the present invention may contain fats and oils containing ⁇ -palmitic acid alone, or may contain fats and oils containing ⁇ -palmitic acid in a mixture with other ingredients.
  • the content of fats and oils containing ⁇ -palmitic acid in the compositions and agents of the present invention may be, for example, 0.1 to 20% by mass, and is preferably 1 to 9% by mass.
  • composition and agent of the present invention may contain other fats and oils, such as fats and oils containing medium-chain fatty acids (e.g., medium-chain fatty acid glycerides) and general edible fats and oils (e.g., fats and oils mainly composed of long-chain fatty acids, such as olive oil and soybean oil), in addition to fats and oils containing ⁇ -palmitic acid.
  • the content of fats and oils other than fats and oils containing ⁇ -palmitic acid in the composition and agent of the present invention can be, for example, 0 to 99% by mass, and is preferably 10 to 40% by mass.
  • composition and agent of the present invention may contain other fats and oils, such as fats and oils containing medium-chain fatty acids (e.g., medium-chain fatty acid glycerides) and general edible fats and oils (e.g., fats and oils mainly composed of long-chain fatty acids, such as olive oil and soybean oil), in addition to fats and oils containing ⁇ -palmitic acid.
  • the content of fats and oils other than fats and oils containing ⁇ -palmitic acid in the composition and agent of the present invention can be, for example, 0 to 99% by mass, and is preferably 10 to 40% by mass.
  • ⁇ -palmitic acid increases mitochondrial ATP production. According to the Examples below, it was also confirmed that ⁇ -palmitic acid increases the expression levels of the Sirt3 gene, Nfe2l2 gene, Tfam gene, Nrf1 gene, and Pgc-1 ⁇ gene.
  • ⁇ -palmitic acid increases the expression levels of the Sirt3 gene, Nfe2l2 gene, Tfam gene, Nrf1 gene, and Pgc-1 ⁇ gene.
  • mitochondrial biogenesis-related genes are referred to as "mitochondrial biogenesis-related genes," and the specific functions of each gene are as follows:
  • the SIRT3 protein encoded by the "Sirt3 gene” is activated by NAD + , activates Foxo3 and ROS decomposition enzymes that decompose reactive oxygen species (ROS) by deacetylation, and eliminates ROS to suppress damage to mitochondrial DNA (mtDNA) and cells. It has also been reported that transcription of the Sirt3 gene is promoted by the NFE2L2 protein (Yue Qian, et al., Oxid Med Cell Longev., 26; 9423593 (2020)., Judith Hagenbuchner, et al., Front Physiol., 20; 4: 147 (2013)., F Kyle Satterstrom, et al., Aging Cell., 14(5): 818-25 (2015).).
  • NFE2L2 protein encoded by the "Nfe2l2 gene” promotes mitochondrial biogenesis by contributing to the maintenance of the expression levels of the Nrf1 gene and PGC-1 ⁇ gene, contributes to the maintenance of mitochondrial structure and functionality, that transcription of the Nfe2l2 gene is promoted by activated PGC-1 ⁇ , and that the Nfe2l2 gene is also activated by reactive oxygen species, inflammatory cytokines, and endoplasmic reticulum stress (Di nkova-Kostova AT, et al., Free Radic Biol Med.
  • TFAM protein encoded by the "Tfam gene” is a transcription factor encoded by nuclear DNA that is responsible for controlling mitochondrial function. It has been reported that upon transfer to mitochondria, it stabilizes mtDNA, promotes the synthesis of electron transport chain complexes encoded by mtDNA, and promotes mtDNA transcription and replication, and that the transcription of the Tfam gene is promoted by NRF1 and NFE2L2 proteins (Yue Qian, et al., Oxid Med Cell Longev., 26; 9423593 (2020)., Melania Collu-Marchese, et al., Biosci Rep. 35(3):e00221(2015).).
  • Nrf1 mitochondrial transcription factor A
  • mtTFA mitochondrial transcription factor A
  • mtDNA transcription and amplification factor mitochondrial transcription factor A
  • PGC-1 ⁇ activated PGC-1 ⁇
  • PGC-1 ⁇ protein encoded by the "Pgc-1 ⁇ gene” is activated through phosphorylation by AMPK, deacetylation by SIRT1, and phosphorylation by p38MAPK, and that activated PGC-1 ⁇ contributes to mitochondrial biogenesis by promoting the biosynthesis of NRF1, NFE2L2, and TFAM (Katsutaro Morino et al., Diabetes, 49(11): 837-840(2006); Melania Collu-Marchese, et al., Biosci Rep. 35(3):e00221(2015); Richard C Scarpulla, Biochim Biophys Acta. 1813(7): 1269-78(2011)).
  • mitochondrial biogenesis-related genes suggest that mitochondrial biogenesis is promoted by the ⁇ "Nfe2l2 gene"-"Sirt3 gene”> pathway and the ⁇ "Pgc-1 ⁇ gene"-"Nrf1 gene/Nfe2l2 gene”-"Tfam gene”> pathway, respectively. And, without being bound by the following theory, in light of the results of the examples described below, it is presumed that ⁇ -palmitic acid acts on the expression of the Nfe2l2 gene and/or the Pgc-1 ⁇ gene (particularly the expression of the Nfe2l2 gene), resulting in upregulation of the expression of the Sirt3 gene and the Tfam gene.
  • ⁇ -palmitic acid can increase the amount of mitochondrial ATP production and enhance the expression of mitochondrial biogenesis-related genes.
  • ⁇ -palmitic acid can be used to promote mitochondrial ATP production and enhance the expression of mitochondrial biogenesis-related genes (preferably one or more genes selected from the group consisting of the Sirt3 gene, the Nfe2l2 gene, and the Tfam gene), and can also be used to improve mitochondrial function.
  • mitochondrial function refers to mitochondrial functions such as ATP production, mitochondrial biogenesis (e.g., synthesis of electron transport complexes), activation of electron transport complexes, oxidative stress regulation (e.g., suppression of damage to mitochondrial DNA and cells caused by reactive oxygen species (ROS)), and control of cell death.
  • mitochondrial function refers to enhancing the mitochondrial function of a subject. Subjects include humans and non-human animals, and non-human animals are preferably non-human mammals (e.g., mice, rats, guinea pigs, horses, cows, monkeys, rabbits, pigs, dogs, and cats).
  • compositions and agents of the present invention can be provided in the form of medicines and quasi-drugs (e.g., pharmaceutical compositions), foods (e.g., food compositions), feeds (e.g., feed compositions), etc., and can be implemented as described below.
  • medicines and quasi-drugs e.g., pharmaceutical compositions
  • foods e.g., food compositions
  • feeds e.g., feed compositions
  • the oils and fats containing ⁇ -palmitic acid can be orally administered to humans and non-human animals.
  • Oral preparations include granules, powders, tablets (including sugar-coated tablets), pills, capsules, syrups, emulsions, and suspensions. These preparations can be formulated using pharma- ceutical acceptable carriers by methods commonly used in the field.
  • Pharmaceutically acceptable carriers include excipients, binders, diluents, additives, flavorings, buffers, thickeners, colorants, stabilizers, emulsifiers, dispersants, suspending agents, preservatives, etc.
  • the oils and fats containing ⁇ -palmitic acid can be administered to humans and non-human animals by methods other than oral administration, such as feeding tube administration and nasal feeding tube administration, depending on the form of the composition and agent of the present invention.
  • oral administration such as feeding tube administration and nasal feeding tube administration
  • the composition and agent of the present invention by making the composition and agent of the present invention into a viscous liquid composition containing oils and fats containing ⁇ -long-chain saturated fatty acids, or a semi-solid composition containing oils and fats containing ⁇ -long-chain saturated fatty acids, it can be ingested or administered to humans and non-human animals who have reduced chewing and swallowing functions and are unable to take orally or administer the composition or agent.
  • composition and agent of the present invention ingested or administered by methods other than oral intake, it is expected that the mitochondrial function of the subject to be ingested or administered can be improved, even if the chewing and swallowing functions of the subject to be ingested or administered have decreased due to aging, etc.
  • fats and oils containing ⁇ -palmitic acid can be orally ingested by humans and non-human animals.
  • fats and oils containing ⁇ -palmitic acid may be in an isolated, purified or crude form, or in the form of a food or food ingredient containing fats and oils containing ⁇ -palmitic acid.
  • the fats and oils containing ⁇ -palmitic acid when provided as food, the fats and oils can be contained in the food, and such foods contain an effective amount of fats and oils containing ⁇ -palmitic acid.
  • foods or ingredients that already contain the fats and oils when provided as the food of the present invention, and such foods contain an effective amount of fats and oils containing ⁇ -palmitic acid.
  • containing an effective amount of fats and oils containing ⁇ -palmitic acid refers to a content such that fats and oils containing ⁇ -palmitic acid are ingested in the range described below when the amount normally consumed in each food is ingested.
  • food is used to mean health foods, functional foods, health functional foods (e.g., foods for specified health uses, foods with nutritional functions, foods with functional claims), foods for special dietary uses (e.g., foods for people with difficulty swallowing, infant formula, powdered milk for pregnant and lactating women, foods for sick people), nutritional supplements, and foods for infants.
  • the form of the "food” is not particularly limited, and may be, for example, a liquid form such as a beverage or liquid food, a paste, semi-liquid, gel, or a solid, bar, or powder form.
  • a liquid form such as a beverage or liquid food
  • a paste, semi-liquid, gel, or a solid, bar, or powder form When the composition and agent of the present invention are used in the form of a powder, they can be manufactured by using means such as spray drying or freeze drying.
  • the composition and agent of the present invention are provided as a food containing fats and oils containing ⁇ -palmitic acid, they can be manufactured according to a normal food manufacturing method, except for blending fats and oils containing ⁇ -palmitic acid. That is, the food of the present invention can be prepared by adding fats and oils containing ⁇ -palmitic acid, regardless of their form (liquid, solid, powder, etc.), to various foods (e.g., milk, soft drinks, fermented milk, yogurt, chocolate, gummies, cheese, bread, biscuits, cookies, crackers, pizza crust, jelly, ice cream, high-energy supplements, high-energy pastes, modified milk powder, liquid diets, special dietary foods, foods for sick people, complete nutritional foods, dietary supplements, frozen foods, processed foods, and other commercially available foods) or their ingredients.
  • various foods e.g., milk, soft drinks, fermented milk, yogurt, chocolate, gummies, cheese, bread, biscuits, cookies, crackers, pizza crust, jelly, ice cream,
  • subjects can ingest fats and oils containing ⁇ -palmitic acid in various forms (liquid, solid, powder, paste, etc.) by adding them to water, food, drink, or meals.
  • fats and oils containing ⁇ -palmitic acid in various forms (liquid, solid, powder, paste, etc.) by adding them to water, food, drink, or meals.
  • by blending an effective amount of oils and fats containing ⁇ -palmitic acid into a liquid diet it is possible to produce a food that also has the effect of improving mitochondrial function, and such a food is advantageous because it can be ingested or administered to sick or elderly people with reduced chewing or swallowing functions.
  • composition and agent of the present invention are provided in the form of a food or raw material (particularly a processed raw material) that already contains fats and oils containing ⁇ -palmitic acid
  • examples of such foods and raw materials include edible fats and oils such as lard and vegetable oils and fats.
  • composition and agent of the present invention can be administered to subjects of any age, but are suitable for administration to subjects in which improved mitochondrial function is desired.
  • Preferred subjects include, for example, infants, who are expected to quickly adapt to aerobic mitochondrial respiration, and middle-aged and elderly people (e.g., 65 years or older), who have a high need to suppress the decline in mitochondrial function with age.
  • Subjects who take or administer the compositions and agents of the present invention can be subjects in a state of reduced mitochondrial function.
  • subjects with reduced mitochondrial function can be identified, for example, using as an indicator the mRNA expression level and/or protein expression level of mitochondrial biogenesis-related genes in a biological sample (e.g., blood, saliva).
  • a biological sample e.g., blood, saliva
  • the subject can be identified as a subject in a state of reduced mitochondrial function.
  • the "reference value" can be determined, for example, by calculation from the mRNA expression level and/or protein expression level of the mitochondrial biogenesis-related gene in a biological sample of a subject with normal mitochondrial function (normal subject).
  • the normal subject is typically a healthy person.
  • the average value, median value, percentile value, maximum value, or minimum value of the normal subject can be used.
  • the percentile value can be any value, for example, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 75, 80, 85, 90, or 95.
  • the number of normal subjects when calculating the reference value is preferably multiple, for example, 2 or more, 5 or more, 10 or more, 20 or more, 50 or more, or 100 or more.
  • the reference value is a value for identifying a subject with reduced mitochondrial function, and in this sense can be called a cutoff value or a boundary value.
  • the "reference value" can also be calculated based on the mRNA expression level and/or protein expression level of the mitochondrial biogenesis-related gene in a biological sample from a subject with normal mitochondrial function (normal subject) and the mRNA expression level and/or protein expression level of the mitochondrial biogenesis-related gene in a biological sample from a subject with reduced mitochondrial function (subject with reduced function).
  • the reference values can be set for the subjects with reduced mitochondrial function and normal subjects by performing statistical analysis such as ROC (Receiver Operating Characteristic) analysis using the mRNA expression level and/or protein expression level of the mitochondrial biogenesis-related gene in the biological sample.
  • ROC Receiveiver Operating Characteristic
  • the subject when the mRNA expression level and/or protein expression level of a mitochondrial biogenesis-related gene in a biological sample from a subject is lower than the average expression level of the gene in normal subjects, or is about 0.9 times or less, about 0.85 times or less, about 0.8 times or less, about 0.75 times or less, about 0.7 times or less, about 0.65 times or less, about 0.6 times or less, about 0.55 times or less, about 0.5 times or less, about 0.45 times or less, about 0.4 times or less, or about 0.35 times or less compared to the average expression level, the subject can be identified as having reduced mitochondrial function.
  • the number of mitochondrial biogenesis-related genes may be one or more, preferably three or more, more preferably four or more, and even more preferably five.
  • the composition and agent of the present invention can be used for anti-aging or suppression of cellular aging.
  • the cells to be targeted for aging suppression include, but are not limited to, cells that constitute metabolically active organs (e.g., liver, kidney, muscle, brain, heart), and specifically include liver cells, kidney cells, muscle cells, brain cells, cardiac cells, etc.
  • aging generally refers to changes (decline) in physiological functions that occur after maturity, and more specifically includes, for example, changes in the cardiovascular system, such as coronary artery sclerosis and a decrease in maximum cardiac output during exercise; changes in the respiratory system, such as a decrease in the number of alveoli and a decrease in lung elasticity; changes in the digestive system, such as aspiration pneumonia due to a decrease in chewing or swallowing ability, constipation and abnormal bowel movements due to a decrease in gastrointestinal motility, and reflux esophagitis due to the reflux of gastric contents into the esophagus; changes in the renal and urinary systems, such as loss of glomeruli, decreased renal blood flow, and decreased filtration rate; changes in the skeletal system, such as osteoporosis and fractures due to a decrease in bone mass and bone density, and arthritis due to a decrease in joint fluid and decreased elasticity of the synovial membrane; and changes in audiovisual functions, such as decreased eyesight and hearing loss.
  • changes in the cardiovascular system such as
  • anti-aging includes maintaining the state before and after aging changes (i.e., at least maintaining the state before and after aging changes as they are, and preferably inhibiting or preventing changes (e.g., deterioration) in the state before and after aging changes), as well as improving the state before and after aging changes (i.e., improving the state before and after aging changes).
  • cellular senescence refers to a state in which mitochondrial function of cells is reduced with age and a state in which mitochondrial biogenesis in cells is reduced.
  • inhibittion of cellular senescence includes maintaining the state before and after changes due to cellular senescence (i.e., maintaining at least the state before and after changes due to cellular senescence as they are, and preferably inhibiting or preventing changes (e.g., deterioration) in the state before and after changes due to cellular senescence), as well as improving the state before and after changes due to cellular senescence (i.e., improving the state before and after changes due to cellular senescence).
  • compositions and agents of the present invention can be taken not only by healthy individuals, but also by subjects who have developed a disease associated with decreased mitochondrial function or subjects who have decreased mitochondrial function.
  • ⁇ -palmitic acid can be used to maintain, improve, treat or prevent diseases and conditions that can be maintained, improved, treated or prevented by improving mitochondrial function.
  • “improvement” means making a certain condition better.
  • “maintenance” means keeping a certain condition at least as it is, and includes suppressing or preventing a certain condition from changing.
  • “A certain condition” includes a changed condition and a normal condition
  • "normal condition” includes the condition before the change.
  • “change” is, for example, deterioration.
  • one aspect of “improvement” is the recovery of a deteriorated condition.
  • one aspect of "maintenance” is the suppression or prevention of deterioration of a deteriorated condition or a normal condition.
  • oils and fats containing ⁇ -palmitic acid can be combined with other ingredients and provided as compositions or supplements aimed at improving mitochondrial function.
  • the daily intake or administration amount of the composition and agent of the present invention as a medicine or food is not particularly limited, since it varies depending on the pathology, age, symptoms, weight, and use of the subject.
  • the daily intake or administration amount (converted to solid content) of fats and oils containing ⁇ -palmitic acid for an adult is not particularly limited, but the lower limit is, for example, 0.01 g, preferably 0.1 g.
  • the upper limit is, for example, 65 g or 60 g, preferably 5 g or 1 g. These lower and upper limits can be combined arbitrarily.
  • the number and frequency of intake or administration can be appropriately determined depending on the degree of improvement of mitochondrial function required.
  • the intake amount and administration amount, as well as the intake interval and administration interval, can be determined by the subject's doctor, pharmacist, registered dietitian, nutritionist, care worker, care manager, helper, staff of a care facility, caregivers such as the subject's family, or the subject himself/herself.
  • composition and agent of the present invention may be used in combination with other compositions and agents that can be taken orally without any restrictions.
  • the effect of improving mitochondrial function can be further enhanced by using the composition and agent in combination with materials or compositions that are expected to have anti-aging effects, such as antioxidants.
  • composition and agent of the present invention can be provided as a composition and agent with a daily intake amount effective for improving mitochondrial function.
  • the composition and agent of the present invention may be packaged so that an effective daily intake amount of oils and fats containing ⁇ -palmitic acid can be ingested, and the packaging form may be a single package or multiple packages as long as an effective daily intake amount can be ingested.
  • the packaging form may be a single package or multiple packages as long as an effective daily intake amount can be ingested.
  • the package has a description regarding the intake amount so that an effective daily intake amount can be ingested, or that a document with such description is provided together with the composition and agent.
  • multiple packages of the effective daily intake amount can be provided as a set for convenience of ingestion.
  • the packaging form for providing the compositions and agents of the present invention is not particularly limited as long as it specifies a certain amount, and examples include wrapping paper, bags, soft bags, paper containers, cans, bottles, capsules, and other containers that can accommodate the composition and agents.
  • the administration and ingestion period is preferably two weeks or more (e.g., 2 to 14 weeks), and more preferably three weeks or more (e.g., 3 to 21 weeks).
  • “continuously” means that the compositions and agents of the present invention are administered or ingested continuously at least once per week (e.g., 1 to 7 times).
  • the compositions and agents of the present invention are provided in a packaged form, they may be provided as a set containing an effective intake amount for a certain period (e.g., one week) for continuous ingestion.
  • the food of the present invention may be labeled with a label indicating that it has an effect of improving mitochondrial function.
  • the food of the present invention may be labeled with, for example, some or all of the following labeling: ⁇ For those who want to extend their healthy lifespan ⁇ For those who are concerned about aging ⁇ To slow down the changes that accompany cellular aging
  • a method for improving mitochondrial function or a method for enhancing expression of mitochondrial biogenesis-related genes comprising ingesting or administering to a subject in need thereof an effective amount of an oil or fat containing ⁇ -palmitic acid or a composition containing the same.
  • the present invention also provides a method for maintaining, improving, treating or preventing a disease or condition that can be maintained, improved, treated or prevented by improving mitochondrial function, comprising ingesting or administering to a subject in need thereof an effective amount of an oil or fat containing ⁇ -palmitic acid or a composition containing the same.
  • the method of the present invention can be carried out according to the description of the composition and agent of the present invention.
  • an oil containing ⁇ -palmitic acid or a composition comprising the same as an agent for improving mitochondrial function or an agent for enhancing expression of mitochondrial biogenesis-related genes, or in a method for improving mitochondrial function or a method for enhancing expression of mitochondrial biogenesis-related genes, for the manufacture of an agent for improving mitochondrial function or an agent for enhancing expression of mitochondrial biogenesis-related genes, or in a method for improving mitochondrial function or a method for enhancing expression of mitochondrial biogenesis-related genes.
  • an oil containing ⁇ -palmitic acid or a composition comprising the same as an agent for maintaining, improving, treating or preventing a disease or condition that can be maintained, improved, treated or prevented by improving mitochondrial function, for the manufacture of an agent for maintaining, improving, treating or preventing a disease or condition that can be maintained, improved, treated or prevented by improving mitochondrial function, or in a method for maintaining, improving, treating or preventing a disease or condition that can be maintained, improved, treated or prevented by improving mitochondrial function.
  • the use of the present invention can be carried out according to the description of the composition and agent of the present invention and the method of the present invention.
  • an oil containing ⁇ -palmitic acid or a composition comprising the same for use in improving mitochondrial function or enhancing expression of mitochondrial biogenesis-related genes.
  • the present invention also provides an oil containing ⁇ -palmitic acid or a composition comprising the same for use in maintaining, improving, treating or preventing a disease or condition that can be maintained, improved, treated or prevented by improving mitochondrial function.
  • non-therapeutic does not mean to include surgery, therapy, or diagnosis of humans (i.e., medical procedures on humans), and specifically does not include methods of surgery, therapy, or diagnosis performed on humans by a physician or a person under the direction of a physician.
  • Example 1 Effect of ⁇ -palmitic acid on the amount of ATP produced
  • Example 1 the effect of ⁇ -palmitic acid on the amount of ATP produced was examined.
  • the final concentration of BSA was 0.1%
  • the final concentration of EtOH was 0.01%.
  • the amount of ATP production was measured using the ATP Assay Kit-Luminescence (Dojindo Laboratories) according to the kit protocol. Statistical analysis was performed by one-way ANOVA followed by multiple comparison test by Tukey-Kramer method.
  • Example 2 Effect of ⁇ -palmitic acid on the expression levels of mitochondrial biogenesis-related genes (1) In Example 2, the effect of ⁇ -palmitic acid on the expression level of mitochondrial biogenesis-related genes was examined.
  • Example 3 Effect of ⁇ -palmitic acid on the expression levels of mitochondrial biogenesis-related genes (2) In Example 3, the test substances were increased and the effect of ⁇ -palmitic acid on the expression level of mitochondrial biogenesis-related genes was further examined.
  • test was carried out in the same manner as in Example 2(1) above, except that 2-monopalmitin (CAS number: 23470-00-0, Cayman Chemical Company), 2-monomyristin (CAS number: 3443-83-2, Larodan AB), palmitic acid (CAS number: 57-10-3, Cayman Chemical Company), and 2-monostearin (CAS number: 621-61-4, Larodan AB) were used as test substances.
  • 2-monopalmitin CAS number: 23470-00-0, Cayman Chemical Company
  • 2-monomyristin CAS number: 3443-83-2, Larodan AB
  • palmitic acid CAS number: 57-10-3, Cayman Chemical Company
  • 2-monostearin CAS number: 621-61-4, Larodan AB
  • Example 4 Preparation of infant food composition
  • an infant food composition (formulated powdered milk) was prepared according to the composition (per 100 kcal) in Table 4.
  • beverages, jelly drinks, powdered drinks, solid preparations, powdered preparations, etc. can be produced by known methods.
  • Example 5 Preparation of food composition for the elderly
  • a food composition for the elderly was prepared according to the composition (per 100 ml) in Table 5.
  • beverages, jelly drinks, powdered drinks, solid preparations, powdered preparations, etc. can be produced by known methods.
  • the present invention makes it possible to provide a method for producing a food for improving mitochondrial function that contains ⁇ -palmitic acid as an active ingredient.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une nouvelle composition améliorant la fonction mitochondriale. La présente invention concerne une composition améliorant la fonction mitochondriale contenant comme principe actif une graisse qui contient un acide palmitique en position β. La présente invention concerne également une composition améliorant l'expression génique liée à la biosynthèse mitochondriale, contenant comme principe actif une graisse qui contient un acide palmitique en position β. La présente invention entraîne un effet d'amélioration de la fonction mitochondriale et présente l'avantage d'être très sûre, en ce que même l'ingestion continue sur une longue période de temps ne provoque pas d'effet secondaire préoccupant.
PCT/JP2023/035000 2022-09-27 2023-09-26 Composition améliorant la fonction mitochondriale WO2024071138A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022153569 2022-09-27
JP2022-153569 2022-09-27

Publications (1)

Publication Number Publication Date
WO2024071138A1 true WO2024071138A1 (fr) 2024-04-04

Family

ID=90478034

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/035000 WO2024071138A1 (fr) 2022-09-27 2023-09-26 Composition améliorant la fonction mitochondriale

Country Status (1)

Country Link
WO (1) WO2024071138A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845490A1 (fr) * 2013-09-05 2015-03-11 Loders Croklaan B.V. Composition gras pour améliorer la répartition du tissu adipeux
JP2019162055A (ja) * 2018-03-19 2019-09-26 株式会社明治 エネルギー代謝促進用組成物
JP2022159178A (ja) * 2021-03-31 2022-10-17 株式会社明治 抗老化用組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845490A1 (fr) * 2013-09-05 2015-03-11 Loders Croklaan B.V. Composition gras pour améliorer la répartition du tissu adipeux
JP2019162055A (ja) * 2018-03-19 2019-09-26 株式会社明治 エネルギー代謝促進用組成物
JP2022159178A (ja) * 2021-03-31 2022-10-17 株式会社明治 抗老化用組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TRINCHESE GIOVANNA, CAVALIERE GINA, DE FILIPPO CHIARA, ACETO SERENA, PRISCO MARINA, CHUN JONG TAI, PENNA EDUARDO, NEGRI ROSSELLA, : "Human Milk and Donkey Milk, Compared to Cow Milk, Reduce Inflammatory Mediators and Modulate Glucose and Lipid Metabolism, Acting on Mitochondrial Function and Oleylethanolamide Levels in Rat Skeletal Muscle", FRONTIERS IN PHYSIOLOGY, vol. 9, 1 January 2018 (2018-01-01), CH , pages 1 - 15, XP093151685, ISSN: 1664-042X, DOI: 10.3389/fphys.2018.00032 *
寺田新. 脂肪酸の種類や油脂の構造による消化・吸収および代謝の違い. 化学と教育. 2013, vol. 61, no. 6, pp. 282-285, (TERADA, Shin. Chemistry & Education), non-official translation (Differences Between Digestion/Absorption and Metabolism Based on Fatty Acid Type and Fat Structure.) *

Similar Documents

Publication Publication Date Title
RU2751638C2 (ru) Композиции, содержащие никотинамидрибозид и уролитин
JP2023100869A (ja) 対象におけるマイトファジーを改善するための方法
WO2011077800A1 (fr) Agent permettant d'améliorer une hyperlipémie, composition permettant d'améliorer une anémie, composition permettant de réduire le taux d'acide urique et aliments et boissons
US20170035725A1 (en) Muscle atrophy inhibitor
JP2023100870A (ja) 対象におけるマイトファジーを改善するための方法
JP2009173634A (ja) ポリ−γ−グルタミン酸を含有する脂質吸収阻害剤
KR20080108523A (ko) 지방 축적 억제제
WO2004105739A1 (fr) Compositions, aliments et boissons contenant un derive d'acide gras superieur
BR112020016923A2 (pt) Método para reverter ou atenuar lesão, ou fraqueza ou perda óssea, ou para evitar fraturas em um indivíduo, e, composição
WO2020009111A1 (fr) Composition pour l'inhibition de l'accumulation de graisse
US8486899B2 (en) Antioxidant
US10695317B2 (en) Composition for promoting production of brain-derived neurotrophic factor
JP2022159178A (ja) 抗老化用組成物
JP2010222284A (ja) 血中ｇｉｐ上昇抑制剤
WO2024071138A1 (fr) Composition améliorant la fonction mitochondriale
WO2019181822A1 (fr) Composition pour accélérer le métabolisme énergétique
US9801404B2 (en) IGF-1 production-promoting agent
WO2007132714A1 (fr) Agent servant à accroître la densité osseuse
JP7225503B2 (ja) 新規なカカオポリフェノール含有血圧上昇抑制用組成物
JP6903367B1 (ja) 抗肥満用組成物及び経口用組成物
WO2021153708A1 (fr) Analogue du cholestérol présentant une activité anti-helicobacter pylori
KR20090064449A (ko) 신규한 기능식품용 및 약학적 조성물 및 관절 내 연골 분해 또는 연골 손상의 치료, 공동치료 또는 예방을 위한 이의 용도
WO2019112037A1 (fr) Composition pour soulager une inflammation chronique
WO2022255284A1 (fr) Agent destiné à être administré par voie orale pour femmes enceintes
JP2019180399A (ja) 食後の血糖値上昇抑制用組成物